Log in

DiaMedica Therapeutics Stock Forecast, Price & News

-0.11 (-2.55 %)
(As of 10/22/2020 12:00 AM ET)
Today's Range
Now: $4.21
50-Day Range
MA: $4.35
52-Week Range
Now: $4.21
Volume83,220 shs
Average Volume59,643 shs
Market Capitalization$78.89 million
P/E RatioN/A
Dividend YieldN/A
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:DMAC



Sales & Book Value

Annual Sales$500,000.00
Book Value$0.64 per share


Net Income$-10,650,000.00


Market Cap$78.89 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
-0.11 (-2.55 %)
(As of 10/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

How has DiaMedica Therapeutics' stock been impacted by Coronavirus (COVID-19)?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DMAC shares have increased by 5.3% and is now trading at $4.21.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of DiaMedica Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DiaMedica Therapeutics

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for DiaMedica Therapeutics

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced its earnings results on Tuesday, August, 11th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02.
View DiaMedica Therapeutics' earnings history

What price target have analysts set for DMAC?

3 Wall Street analysts have issued 12 month price objectives for DiaMedica Therapeutics' shares. Their forecasts range from $14.00 to $15.00. On average, they expect DiaMedica Therapeutics' share price to reach $14.33 in the next twelve months. This suggests a possible upside of 240.5% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a drop in short interest in September. As of September 15th, there was short interest totaling 20,600 shares, a drop of 21.1% from the August 31st total of 26,100 shares. Based on an average daily volume of 52,100 shares, the short-interest ratio is currently 0.4 days.
View DiaMedica Therapeutics' Short Interest

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Dietrich John Pauls M.B.A., MBA, Pres, CEO & Director (Age 49, Pay $612.65k)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 55, Pay $341.25k)
  • Dr. Harry W. Alcorn Jr., Chief Medical Officer (Age 64, Pay $356.55k)
  • Dr. Edward G. Calamai, Consulting Head of Manufacturing

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $4.21.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $78.89 million and generates $500,000.00 in revenue each year. DiaMedica Therapeutics employs 8 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]

This page was last updated on 10/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.